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The low level of DNA methylation in tumors compared to the level of DNA methylation 
in their normal-tissue counterparts or global DNA hypomethylation was one of the first 
epigenetic alterations to be found in human cancer1, 2. While the contribution of genome 
hypomethylation in cancer development and progression is explained by several 
mechanisms: chromosomal instability, loss of imprinting, and reactivation of 
transposable elements3, 4, the molecular causes of genome hypomethylation remain 
unclear. Indeed, despite the central roles of the DNA methyltransferases (Dnmts) in the 
establishment and maintenance of the DNA methylation, no clear consensus appears 
between the reduction of the Dnmts expression and the genome hypomethylation in 
human cancers5. Nevertheless, the cancer-associated genome hypomethylation could be 
explained by the disruption of interactions existing between Dnmts and the DNA 
replication and DNA repair proteins because these interactions play a crucial role in the 
DNA methylation in mammalian cells6-8. We here demonstrate that the disruption of the 
Dnmt1/PCNA and Dnmt1/UHRF1 interactions induce the genome hypomethylation and 
act as oncogenic factors promoting the tumorigenesis. We also identify the Akt- and/or 
PKC-mediated phosphorylations of Dnmt1 as both initiators of these disruptions and as 
a hallmark conferring poor prognosis in glioma patients. 
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The global DNA methylation status of gliomas was assessed by measuring the number 
of 5-methylcytosine (5mC) in a collection of 62 surgical resections of gliomas and in 5 non-
pathologic brain biopsies (Figure 1a). ELISA results indicate that the 5mC number decreases 
when the glioma grade increases (Pearson’s correlation test, r=-0.504, p<0.0001). We next 
complemented this observation by measuring the intra-tumor de novo and maintenance DNA 
methyltransferase activities (dnMTase and mMTase) in order to determine the contribution of 
each MTase activities on the global DNA hypomethylation phenotype characterizing the 
gliomagenesis. Each MTase activity was plotted against the 5mC data and a statistical 
analysis using the Pearson’s correlation test showed a significant correlation between the 5mC 
and the mMTase activity (r=0.760, p<0.0001), but not between the 5mC and the dnMTase 
activity (r=0.135, p=0.2761) (Figure 1b). The Dnmt1 being the predominant maintenance 
methyltransferase enzyme, we next assessed its expression in glioma biopsies by ELISA. No 
significant correlation was observed between the Dnmt1 expression and the mMTase activity 
(Pearson’s correlation test, r=-0.202, p=0.1012) (Figure 1c). Gliomagenesis involving a 
stepwise accumulation of kinases, we decided to determinate whether the Dnmt1 
phosphorylation was a molecular determinant governing the mMTase activity decrease seen 
above. For this purpose, we estimated the amount of phosphorylated Dnmt1 (pDnmt1) by 
ELISA using a panel of motif specific antibodies (phospho-Akt substrate-specific (PAS), 
phospho-(ser)-PKC substrate (PPCS), phospho-(thr)- and phospho-(ser)-CDK substrate 
(PCS)). pDnmt1-PAS, pDnmt1-PPCS, and pDnmt1-PCS values were plotted against the 
mMTase activity values. Significant inverse correlations were observed between the pDnmt1-
PAS or the pDnmt1-PPCS levels and the mMTase activity (Pearson’s correlation test, r=-
0.569, p<0.0001 and r=-0.454, p=0.0001), but not between the pDnmt1-PCS and the mMTase 
activity (Pearson’s correlation test, r=-0.045, p=0.7177) (Figures 1d and S1). 
We next analyzed whether the presence of high quantities of both pDnmt1-PAS and pDnmt1-
PPCS could affect the survival time of a subgroup of 53 glioma patients for which we 
obtained a well-documented medical history (Table S1). Based on the pDnmt1-PAS and 
pDnmt1-PPCS levels found on tumor biopsies, the 53 patients were divided into two groups. 
18 patients whose tumors expressed high levels of pDnmt1-PAS and pDnmt1-PPCS 
simultaneously (equal to or higher than the median value of considered grade) were included 
in group#1 (in grey on table S1), while 35 patients whose tumors are devoid of this hallmark 
composed the group#2. Survival curves were estimated by the Kaplan-Meier method and 
compared with the Cox proportional hazards survival regression test (Figure 1e). Thus, we 
observed a significant difference in survival time between patients whose tumors had a high 
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pDnmt1-PAS and pDnmt1-PPCS levels and those whose did not (p=0.001). These results 
indicate that the high presence of Akt- and PKC-phosphorylated forms of Dnmt1 could be 
used as an alternative molecular biomarker to predict the disease outcome and/or the 
prognosis of glioma. 
To assess the impact of the Akt- and PKC-phosphorylations of Dnmt1 on the 
functionality of this enzyme in glioma cells with characteristics similar to the cells present in 
the tumor mass, we next decided to extend our analyses to primary cultured tumor cells 
(PCTC) obtained from gliomas because established cell lines diverged from original cells9. 
ELISA, DMB assay and immunoblots confirmed that PCTCs (as tumors) are characterized by 
a decrease of 5mC number, a diminution of the mMTase activity, and an increase of the 
pDnmt1-PAS and/or pDnmt1-PPCS levels all the more important that the tumor grade is 
elevated (Figure 2a). Bisulfite sequencing and Chromatin ImmunoPrecipitation (ChIP) 
corroborated these points by showing that the Alu methylation status and the Dnmt1 
recruitment on this DNA repeat element decreased when the tumor grade increased (Figure 
2b). Consistent with these results, we then characterized the Akt- or PKC-mediated 
phosphorylations of recombinant human Dnmt1 (rh-Dnmt1). Mass spectrometric analyses 
indicated that Akt phosphorylated rh-Dnmt1 at serine-127 and 143 while PKC phosphorylated 
rh-Dnmt1 at serine-127 (Figure 2c and S2). Strikingly, it appears that these phosphorylations 
are included within or juxtapose the interaction domains of Dnmt1 with PCNA and UHRF1 
identified by Chuang et al. (1997)7 and Bostick et al. (2007)6. Thus, we hypothesized that the 
Akt- and PKC-induced Dnmt1 phosphorylations could act as two molecular determinants 
inhibiting the Dnmt1 recruitment on DNA via the disruption of the Dnmt1/PCNA and 
Dnmt1/UHRF1 interactions because PCNA and UHRF1 proteins mediating the epigenetic 
inheritance in mammalian cells by recruiting Dnmt16, 8. This idea was first demonstrated by 
the fact that the Akt and/or PKC-induced phosphorylations of rh-Dnmt1 inhibited the 
Dnmt1/PCNA and/or Dnmt1/UHRF1 interactions in pull down assay, but not the 
Dnmt1/HDAC1 interaction (Figure 2d). Secondly, our hypothesis was validated by the fact 
that the amount of Dnmt1/PCNA and Dnmt1/UHRF1 interactions is (supprimé) correlated 
with the level of Dnmt1 recruited on DNA (Figure 2e). Thirdly, the fact that Akt and PKC 
inhibitor treatments restored the Dnmt1/PCNA and Dnmt1/UHRF1 interactions in PCTCs 
also supported the idea that the Akt- and PKC-induced Dnmt1 phosphorylations negatively 
regulated the Dnmt1/PCNA and Dnmt1/UHRF1 interactions (Figure 2f). Thus, all these 
results demonstrate that the decrease of both Dnmt1/PCNA and Dnmt1/UHRF1 interactions 
for the benefit of the presence of pDnmt1-PAS and pDnmt1-PPCS is a crucial molecular 
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event generating the decrease of 5mC number seen in tumors via the decrease of mMTase 
activities. This last point was demonstrated by DMB assay and the hierarchical classification 
of the mMTase activity effectors namely Dnmt1, pDnmt1-PAS, pDnmt1-PPCS, 
Dnmt1/PCNA and Dnmt1/UHRF1. Indeed, we noted that the Dnmt1/PCNA and 
Dnmt1/UHRF1 dimers catalyzed 5-fold more incorporation of methyl group 3H-radiolabelled 
than pDnmt1-PAS and pDnmt1-PPCS, and 20-fold more incorporation of methyl group 3H-
radiolabelled than the Dnmt1 (Figure 2g). In summary, our data identify Akt- and PKC-
induced phosphorylations of Dnmt1 as the initiators of the disruption of the Dnmt1/PCNA 
and Dnmt1/UHRF1 interactions, and the switch “Dnmt1/PCNA and Dnmt1/UHRF1 to 
pDnmt1-PAS and pDnmt1-PPCS” as the effector of the global DNA hypomethylation 
phenotype seen in tumors. 
We finally wondered whether the global DNA hypomethylation generated disruption of 
Dnmt1/PCNA and Dnmt1/UHRF1 interactions was an event able to transform the Ntv-a glial 
cells into glioma. For this purpose, we designed the peGFP-UP plasmid expressing the 
chimerical protein composed by the GFP reporter protein and by the U and P peptides 
(defined figure 2c), whose expression inhibited the Dnmt1/PCNA and Dnmt1/UHRF1 
interactions but not the Dnmt1/HDAC1 interaction in pull down assay (Figure S3). ELISA 
and immunoprecipitation showed that the Ntv-a/peGFP-UP cells harbored a low level of 5mC 
via the disruption of the Dnmt1/PCNA and Dnmt1/UHRF1 interactions, compared to the Ntv-
a/peGFP cells (Figure 3a). The tumorogenicity of the Ntv-a/peGFP-UP and Ntv-a/peGFP 
cells was assessed by s.c. injection into nude mice and was compared to that of the Ntv-
a/PDGF and Ntv-a/RasAkt cells obtained from the experimental RCAS-system of 
gliomagenesis10, 11. After 2 weeks, we observed macroscopically visible tumors in all 26 
injections of Ntv-a/peGFP-UP cells (Figure 3b). The growth pattern of Ntv-a/peGFP-UP-
induced tumors was similar to that of the tumors formed from the injection of Ntv-a/Ras-Akt 
cells. We also noted that 4/26 Ntv-a/peGFP-UP-induced tumors were invasive (Figure S4). In 
culture, the Ntv-a/peGFP-UP cells harbored several hallmarks of cancer cells namely 
apoptosis evasion, high clonogenicity and high proliferation rate (Figure 3c). At molecular 
level, we observed that the Ntv-a/peGFP-UP cells were characterized by the 
hypomethylation-induced overexpression of BDNF and PDGF-B (Figures 3d and S5). These 
findings confirm that the BDNF and PDGF-B genes are epigenetically regulated12, 13 and 
suggest that the Ntv-a/peGFP-UP cells acquire the cancer hallmark of self-sufficiency in 
growth signals14. Taken together these results strongly demonstrate that the disruption of the 
Dnmt1/PCNA and Dnmt1/UHRF1 interactions acts as an oncogenic factor because this event 
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induces the in vivo tumorogenicity, the acquisition of 3 cancer hallmarks14 (i.e. apoptosis 
evasion, high proliferation and self-sufficiency in growth signals) and the overexpression of 
PDGF-B, an oncogene clearly implicated in gliomagenesis10, 15, 16 (Figure 4). Thus, while 
several papers demonstrate that PCNA and/or UHRF1 play a crucial role in the recruitment 
and/or the anchorage of Dnmt1 on DNA to maintain the DNA methylation pattern of 
mammalian cells via the capacity of these proteins to bind DNA and hemi-methylated DNA6, 
8, 17-19, our work is one of the first to identify the disruption of Dnmt1, PCNA and UHRF1 
interactions as a crucial molecular determinant governing the global DNA hypomethylation 
occurring in tumors. Despite the undoubted role of the chromosomal instability induced by 
the global DNA hypomethylation in the tumorogenesis20, 21, our data suggest that the gene-
specific hypomethylation of oncogenes (like PDGF-B) could be an alternative mechanism 
contributing to the hypomethylation-induced tumor. Due to its oncogenic role, the 
identification of molecular mechanisms governing the Dnmt1, PCNA and UHRF1 
interactions provides new potential therapeutic targets and reinforces the interest to 
investigate the use of Akt and/or PKC inhibitors in the design of anti-glioma therapeutic 
protocols. 
  
METHODS SUMMARY 
 
ELISA. 
Microtiter plate was coated with capture antibody (anti-Dnmt1, Santa Cruz sc-10221, 2μg/ml 
in 100μl of coating buffer) for overnight at 4°C. After 3 washes in PBS/Tween buffer (PBS 
pH 7.2-7.4, Tween-20, 0.05%), microtiter plate was blocked with 200µl /well of blocking 
buffer (PBS pH 7.2, 10% Fetal calf serum) for 30min at room temperature. After 3 washes in 
PBS/Tween buffer, samples are incubated for overnight at 4°C. After 3 washes in PBS/Tween 
buffer, detection antibody (Cell Signaling, Ozyme France) is incubated at the concentration of 
2 µg/ml in 100µl blocking buffer for 1h at room temperature. Revelation is performed by 
inbucating 50 µl/well of alkaline phosphatase conjugated secondary antibody diluted to 1:500 
in blocking buffer at room temperature for 1h. Wells are then washed three times with 
PBS/Tween buffer and once with diethanolamine buffer (10 mM diethanolamine, 0.5 mM 
MgCl2 (pH 9.5) prior to pNPP substrate (Santa Cruz) addition in diethanolamine buffer to a 
final concentration of 1 mg/ml. Reaction is stopped by adding 0.1M EDTA and read on 
microtiter plate reader at OD 405/490. 
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DNA methylation analyses. 
DNA was extracted by using the QiaAmp DNA mini Kit (Qiagen, France) and bisulfite 
conversion was realized by using the EZ DNA methylation Gold kit (Zymo Research – 
Proteigene, France) according to manufacturer’s instructions. Sequencing of bisulfite-
modified DNA was performed on 25 clones generated in two to three independent bisulfite 
modifications. Methylation status of PDGF-B and BDNF were analyzed by Methylation 
Sensitive Restriction Assay (MSRA) and Methylation Specific PCR (MSP) according to the 
primers design by using the MethPrimer program (Figure S4). 
 
Tumorogenicity assay. 
Cultured cells were harvested by trypsinization, washed and resuspended in saline buffer. Cell 
suspensions were injected s.c. as 106 cells in 0.2 ml volume in the flank of 7/8-week-old Nude 
NMRI-nu female mice (Janvier, France). Mice were checked for tumor onset and tumor 
growth twice a week. Tumor parameters were measured by a caliper, and the tumor volumes 
were calculated by multiplying them. 
 
Preparation of Ntv-a/peGFP-UP cells.  
Ntv-a cells come from the laboratory of Eric C. Holland (Memorial Sloan Kettering Cancer 
Center, New York). The peGFP-UP was obtained by subcloning the sequences coding for the 
U and P peptides (defined figure 2c) into the BglII/SacII sites of the peGFP-N plasmid 
(Clontech, France). Ntv-a/peGFP-UP cells were obtained after nucleofection by using the 
Mouse Astrocyte Nucleofector™ kit (Amaxa biosystems, France) according to the 
manufacturer’s instructions. 
 
Statistical Analysis. 
According to the internal committee of bioethics, the overall survival time was measured from 
the date of surgical resection to the last follow-up visit or death. Patients with tumor 
recurrence or partial resection or a Karnofsky Performance Index inferior to 80 were 
censored. Data in bar graphs are expressed as the mean±SD. Each result is representative of 
three independent experiments.  
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LEGENDS. 
 
Figure 1. Presence of high levels of Akt- and PKC-induced phosphorylations of Dnmt1 
confers poor prognosis in glioma patients. 
a, Correlation between the 5-methylcytosine number (5mC) and tumor grade in a collection of 
67 DNA samples including 16 grade II astrocytomas/oligodendrogliomas, 16 grade III 
astrocytomas/oligodendrogliomas, 30 grade IV astrocytomas/GBM and of 5 non-tumor brain 
samples (nt). 5mC was estimated by using the Methylamp Global DNA Methylation 
Quantification kit (Epigentek-Euromedex, France). Dotted lines represent the median of each 
parameter. 
b, Correlation study between the 5-methylcytosine number (5mC) and the de novo (supprimé) 
methyltransferase (dnMTase) or the maintenance methyltransferase (mMTase) activities. 
Intra-tumor mMTase and dnMTase activities were calculated by using hemi-methylated and 
unmethylated DNA substrates in DMB assays according to Yokochi and Robertson (2004)22. 
 represents nt,  represents grade II astrocytomas/oligodendrogliomas, U represents grade 
III astrocytomas/oligodendrogliomas, { represents grade IV astrocytomas/GBM. 
c, Correlation study between relative Dnmt1 expression and the mMTase activity. The 
relative Dnmt1 expression was assessed by using the EpiQuick Dnmt1 assay (Epigentek- 
Euromedex, France).  represents nt,  represents grade II 
astrocytomas/oligodendrogliomas, U represents grade III astrocytomas/oligodendrogliomas, 
{ represents grade IV astrocytomas/GBM. 
d, Correlation study between the mMTase activity and the fraction of Dnmt1 recognized by a 
specific antibody detecting the phospho-Akt substrate (pDnmt1-PAS) and the phospho-PKC 
substrate (pDnmt1-PPCS) (Cell Signaling).  represents nt,  represents grade II 
astrocytomas/oligodendrogliomas, U represents grade III astrocytomas/oligodendrogliomas, 
{ represents grade IV astrocytomas/GBM. 
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e, Kaplan-Meier estimates time of survival between patients suffering from glioma presenting 
a high level of both pDnmt1-PAS and pDnmt1-PPCS (grey line) and those whose tumors did 
not (black line).  
 
Figure 2. The Akt- and/or PKC-induced phosphorylations of Dnmt1 disrupt the 
Dnmt1/PCNA and Dnmt1/UHRF1 interactions. 
a, 5-methylcytosine (5mC) number, maintenance methyltransferase (mMTase) activity and 
level of pDnmt1-PAS and pDnmt1-PPCS in a panel of PCTC issued from the different grade 
of gliomas. 5mC number was assessed by using the Methylamp Global DNA Methylation 
Quantification kit (Epigentek-Euromedex, France). mMTase activities were measured 
according to the method described by Yokochi and Robertson (2004)21. Immunoblots were 
performed from 75μg of proteins and Actin was used as loading control. 
b, Parallel between Dnmt1-recruitement on Alu, a DNA repeat element assessed by 
Chromatin Immunoprecipitation assay (ChIP) and the methylation status of Alu analyzed by 
bisulfite sequencing. ChIP was performed by using the Chromatin EZ-Chip kit (Millipore, 
France) with antibodies specific for of Dnmt1 or GFP (control). The average number of 
methylated CpG is indicated for each glioma grade. 
c, Schematic representation of  Dnmt1. The structural/functional? domains of Dnmt1 are 
delimited according to the data given by on Expasy/UniProtKB/Swiss-Prot (accession number 
P26358) The domains of interaction of Dnmt1 with PCNA (163-174), HDAC1 (686-812) and 
UHRF1 (1-446, 1081-1408 and/or 401-615) are the ones highlighted by Chuang et al. 
(1997)7, Fuks et al. (2000)23, Bostick et al. (2007)6 and Achour et al. (2008)24. The domain of 
UHRF1 interacting with Dnmt1 is also indicated consistent with Achour et al. (2008)23. 
Phosphorylated serines highlighted by mass spectrometry analyses are indicated in figure. 
d, GST pull-down assay analyzing the interactions between the phosphorylated or not 
recombinant human His tagged Dnmt1 (rh-Dnmt1-Methylation Ltd, Port Orange, Florida) and 
GST-UHRF1, GST-HDAC1 or GST-PCNA. All GST pull-down assays were validated by 
immunoblot analysis with anti-Dnmt1 antibody. i represents a loading control of rh-Dnmt1 
and c represents the pull-down realized without GST-fusion protein. 
e, Interaction between Dnmt1 and PCNA and/or UHRF1 and chromatin association of Dnmt1. 
Immunoprecipitations were performed by using the Catch&Release v2.0 reversible 
immunoprecipitation system (Millipore, France). H3 was used as loading control. 
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f, Effect of PKC inhibitor (PKCi or Gö6893, 0.5μM Calbiochem, France) and Akt inhibitor 
(Akti, 0.1μM-Calbiochem#124005, France) treatments on the Dnmt1/PCNA and 
Dnmt1/UHRF1 interactions. PCTCs were treated for 5 consecutive days with PKCi and Akti 
previous to perform Dnmt1 immunoprecipitation from chromatin. The phosphorylation status 
of Dnmt1 was estimated by western blots. 
g, Analysis of the maintenance methyltransferase (mMTase) activity catalyzed by different 
forms of Dnmt1. mMTase activities were assessed by DMB assay according to Yokochi and 
Robertson (2004)21. 
 
Figure 3. The disruption of the Dnmt1/PCNA and Dnmt1/UHRF1 interactions acts as an 
oncogenic factor. 
a, Impact of the GFP-UP protein expression on Dnmt1/PCNA and Dnmt1/UHRF1 
interactions and 5-methylcytosine (5mC) number. These two parameters have been analyzed 
15 days after nucleofection of Ntv-a cells by the peGFP-UP and peGFP plasmids. 
b, Tumorogenicity test of the Ntv-a/peGFP-UP cells. Graph represents the tumor volumes 
obtained after s.c injection of nude mice with Ntv-a/peGFP-UP cells (26 injections), Ntv-
a/peGFP cells (12 injections), Ntv-a/PDGF cells (8 injections) and Ntv-a/Ras-Akt cells (8 
injections). Photographs illustrate the results of a representative injection of Ntv-a/peGFP 
(left) and Ntv-a/peGFP-UP (right) cells (left), of the in situ absence of Ntv-a/peGFP-induced 
tumor cells (middle-top) and of the in situ presence of Ntv-a/peGFP-UP-induced tumors 
(middle-bottom), and the mean volume of Ntv-a/peGFP-UP-induced tumor cells (right-top), 
Ntv-a/PDGF-induced tumor cells (right-middle) and Ntv-a/Ras-Akt-induced tumor cells 
(right-bottom). 
c, Comparison of the apopto-sensitivity (via the measure of DEVDase activity), proliferation 
rate (via the measure of Ki67 expression) and of the clonogenicity index between the Ntv-
a/peGFP and Ntv-a/peGFP-UP cells. DEVDase activity and clonogenicity have been assessed 
as previously described25. Relative Ki67 expression was evaluated by sqPCR (s: 
GACAGCTTCCAAAGCTCACC and as: TGTGTCCTTAGCTGCCTCCT). 
d, Correlation between the PDGF and BDNF proteins and the methylation status of 
corresponding genes. Immunoblots were performed from 75μg of proteins and Actin was 
used as loading control. Methylation status of PDGF and BDNF gene was assessed by 
methylation sensitive restriction assay (MSRA). 
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Figure 4. Schematic representation of gliomagenesis induced by the disruption of the 
Dnmt1/PCNA and/or Dnmt1/UHRF1 interactions. 
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